-
Redefining In Vitro Drug Response Metrics
2026-09-02
Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, separating proliferative arrest from actual cancer cell killing. The framework shows that drugs can influence both processes with different magnitudes and timing, offering a more precise basis for assay selection and preclinical interpretation.
-
Caspase-3/7 Inhibitor I: Assay Guide
2026-09-02
This scenario-based guide explains how Caspase-3/7 Inhibitor I (SKU A1925) can help researchers distinguish caspase-dependent apoptosis from nonspecific loss of viability. It covers selectivity, solvent preparation, controls, interpretation across cell models, and practical criteria for comparing commercial inhibitors.
-
Dabigatran Etexilate: A Translational Map
2026-09-01
Dabigatran etexilate is a direct thrombin inhibitor whose prodrug biology can reshape anticoagulant assay design. This guide connects molecular target engagement, plasma phenotypes, and translational interpretation while clarifying where each readout can mislead.
-
ARL4C Drives Synoviocyte Proliferation in RA
2026-09-01
The reference study combines single-cell RNA sequencing, bulk transcriptomics, cell-based perturbation, coculture experiments, and a collagen-induced arthritis model to identify ARL4C as a regulator of aggressive fibroblast-like synoviocytes in rheumatoid arthritis. Its findings connect ARL4C-dependent synoviocyte proliferation and invasion with macrophage polarization and show that local ARL4C silencing can reduce joint pathology in rats, while also defining important questions for translational validation.
-
Maraviroc: CCR5 Logic for HIV and Stroke
2026-08-31
Maraviroc and UK-427857 provide a precise way to interrogate CCR5 biology, from HIV-1 entry inhibition to carefully bounded neuroinflammation modulation. This article translates an ischemic-stroke inflammation framework into practical assay decisions without overstating evidence for CCR5-directed stroke therapy.
-
DiscoveryProbe Protease Inhibitor Library for HCC
2026-08-31
Use the DiscoveryProbe Protease Inhibitor Library to move from broad protease activity modulation to mechanism-focused validation in biochemical, apoptosis, and cancer research workflows. Its pre-dissolved format and screening-ready plate options support practical hit discovery, while the PSMD14–CARM1–FERMT1 study provides a clear model for connecting protease biology with oncogenic phenotypes.
-
ABT-263 (Navitoclax): Bcl-2 Apoptosis Research
2026-08-30
ABT-263, also called Navitoclax, is an orally bioavailable Bcl-2 family inhibitor used to study mitochondrial apoptosis and cancer-cell survival. Its high affinity for Bcl-2, Bcl-xL, and Bcl-w supports apoptosis assays, while MCL1 expression and mitochondrial priming can influence model sensitivity.
-
GLP-1 (9-36) amide: Assay Workflow Guide
2026-08-29
Use GLP-1 (9-36) amide as a practical blockade tool for separating direct GLP-1 receptor effects from glucagon-driven cAMP responses. This workflow emphasizes peptide handling, FRET-compatible assay design, receptor attribution, and troubleshooting for GLP-1 receptor signaling research and metabolic studies.
-
Guanabenz Acetate for α2 Signaling Workflows
2026-08-28
Guanabenz Acetate provides a defined α2-adrenergic receptor agonist framework for connecting GPCR pharmacology with stress-response and innate-immunity assays. This guide translates subtype potency, DMSO handling, and the SARS-CoV-2 GADD34 study into practical experimental designs, controls, and troubleshooting decisions.
-
Phosbind Acrylamide for Phosphorylation Analysis
2026-08-28
Phosbind Acrylamide enables antibody-free separation of phosphorylated and non-phosphorylated proteins directly in SDS-PAGE, supporting faster pathway experiments and kinase assays. Its strongest use case is comparative analysis of phosphorylation states, including mitotic checkpoint studies where subtle mobility differences can reveal regulated protein populations.
-
AZD6482 Workflow for PI3Kβ Inhibition
2026-08-27
AZD6482 combines subnanomolar biochemical potency with strong PI3Kβ selectivity for pathway, platelet, and metabolic assays. This workflow also shows how to use it as a carefully controlled orthogonal perturbation in RNA-foci experiments inspired by recent Myotonic Dystrophy type 1 research, without confusing hypothesis generation with validated disease biology.
-
PreScission Protease (PSP): Practical Tag Cleavage
2026-08-27
PreScission Protease (PSP), SKU K1101, is a recombinant HRV 3C protease for removing affinity tags from recombinant proteins when the specified recognition sequence is present and accessible. This guide covers sequence checks, low-temperature handling, storage, cleavage setup, and troubleshooting; it should not be treated as evidence for activity on proteins lacking the defined site or for unvalidated cellular applications.
-
25-Hydroxycholesterol Reprograms TAMs via AMPK
2026-08-26
Xiao et al. identify CH25H-derived 25-hydroxycholesterol as a lysosomal immunometabolic checkpoint that activates AMPK and reinforces STAT6-dependent macrophage immunosuppression. The study connects lipid sensing, metabolic reprogramming, ARG1 production, and T-cell exclusion, while showing that CH25H targeting improves anti-tumor activity with or without anti-PD-1 therapy.
-
Levofloxacin Research Workflows for DNA and Bone
2026-08-26
Levofloxacin supports two complementary research tracks: bacterial DNA replication studies and concentration-controlled investigations of osteoblast and cartilage biology. This workflow-focused guide covers stock preparation, exposure design, endpoint selection, comparative interpretation, and troubleshooting for more reproducible assays.
-
CAPE Protects Against C. difficile Through Toxin Inhibition
2026-08-25
Guo et al. identify caffeic acid phenethyl ester (CAPE) as a natural-compound inhibitor of the Clostridioides difficile toxin TcdB and connect toxin suppression with improved outcomes in a murine infection model. The study also links CAPE treatment to changes in gut microbial diversity and metabolites, supporting anti-virulence therapy as a complementary direction for CDI research while highlighting important translational limitations.